Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Best Buy

Conagra Brands

Equity Residential

Entergy

Federal Realty Investment Trust

KeyCorp

Kimco Realty

Kinder Morgan

LyondellBasell Industries

Mid-America Apartment Communities

Altria

Realty Income Corp

ONEOK

Pfizer

Simon Property Group

Truist Financial

Verizon

Long-term bond yields continue to rise. But investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. “23 stocks pay huge dividends. They should be a better bet than treasuries.” —Barron's Weekly. In an interview, Steven Wieting, strategist at Citi-Wealth, noted that a growing-dividend is a tangible-benefit for shareholders and a-hallmark-of companies with strong-balance-sheets. “Nobody can fake a dividend,” he said.

Buy 3 December Barron's Better Bet 'Safer' Dividend Dogs Of 23

Celgene

Bristol-Myers Squibb Company (NYSE:BMY ) Citi's 2024 Global Healthcare Conference December 3, 2024 8:00 AM ET Company Participants Christopher Boerner - CEO and Board Chair David Elkins - EVP and CFO Conference Call Participants Geoff Meacham - Citi Mary Kate Davis - Citi Geoff Meacham Welcome to the first session of the First Annual Global Healthcare Conference at Citi. We're thrilled to be here and we're thrilled to have with us.

Bristol-Myers Squibb Company (BMY) Citi's 2024 Global Healthcare Conference (Transcript)

BOSTON--(BUSINESS WIRE)--AI Proteins, Inc., a biotechnology company that utilizes computational de novo protein design to create therapeutic miniproteins, today announced that it has entered a Research Collaboration and Option Agreement with Bristol Myers Squibb (NYSE: BMY) to discover and develop novel miniprotein-based therapeutics utilizing AI Proteins' powerful discovery platform. Under this collaboration, AI Proteins will leverage its proprietary AI-driven platform to design and optimize m.

AI Proteins Announces Research Collaboration and Option Agreement with Bristol Myers Squibb for Miniprotein-Based Therapeutics Valued up to $400M

AbbVie

Patterson Companies

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields

Bristol-Myers Squibb (BMY -0.08%) is the kind of stock that potentially has a lot to offer to investors looking for wealth-building investments. With a large repertoire of medicines on the market, and a constant stream of programs approaching maturity and a shot at getting approved for sale, there's no question that the business will continue to create drugs that are in demand around the world.

Is Bristol-Myers Squibb Stock a Millionaire Maker?

Finding attractive dividend stocks you can hold isn't too difficult. Finding dividend stocks you can comfortably buy and hold forever is a different story.

3 Magnificent S&P 500 Dividend Stocks Down 27%, 28%, and 29% to Buy and Hold Forever

Johnson & Johnson

Given its better prospects, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pharmaceutical pick over Johnson & Johnson stock (NYSE: JNJ). BMY stock trades at 8.3x its forward expected earnings (2025), versus 14.7x for JNJ.

BMY Stock vs. JNJ Stock

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in Citi's 2024 Global Healthcare Conference.

Bristol Myers Squibb to Participate in Citi's 2024 Global Healthcare Conference

Prime Medicine Inc

Prime Medicine's proprietary Prime Editing platform offers one-time therapeutic solutions, targeting over 90% of genetic conditions across multiple tissues and development stages. PRME's pipeline highlights PM359 for chronic granulomatous disease and preclinical programs for Wilson's Disease, with clinical data expected in 2025. PRME's strategic collaboration with Bristol Myers provided $55 million in cash upfront, a $55 million equity stake, $3.5B in potential milestone payments, and diversification into ex vivo T-cell therapies.

Prime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing Therapies

Bristol-Myers Squibb's price continues to rise due to a confluence of factors, not the least of which is an earnings surprise in Q3 2024. The company's raised guidance for 2024 is also encouraging, as is the FDA's approval for its schizophrenia treatment acquired on buying Karuna Therapeautics earlier this year. Despite a high current P/E ratio, projections for 2025 suggest a massive earnings increase is due, which can potentially double the stock price.

5 Reasons Bristol-Myers Squibb Looks Good Now (Rating Upgrade)

Key Points Donald Trump's victory is positive for the stock market.

One Sector Has Underperformed Massively: These 4 Blue-Chip Dividend Giants Are Huge 2025 Plays

Investors often look to major pharmaceutical stocks as an area that is likely to provide an anchor for their portfolios. Thanks to their supposedly consistent cash flows, they often appear to be capable of steadily growing in value over time.

Where Will Bristol Myers Squibb Be in 5 Years?

Apple

Adams Diversified Equity Fund

Broadcom

Blackrock Inc

ConocoPhillips

Cisco Systems

Chevron

EOG Resources

Enterprise Products Partners

Energy Transfer LP Unit

SPDR Gold Trust

SPDR Gold MiniShares Trust

Alphabet

Home Depot

JPMorgan Nasdaq Equity Premium Income ETF

New Linde PLC

Eli Lilly

Lockheed Martin

MPLX

Marathon Oil

Microsoft

We present a highly diversified yet simple portfolio of 10 positions, with 9 funds and one individual MLP stock. The portfolio has been designed for retirees and investors planning for retirement, with a 6% current income yield and potentially 6% plus dividend growth. The portfolio presented uses a hands-off approach, and it is diversified among many asset classes as well as different sectors of the economy to be able to withstand different economic cycles in the next 10 years.

Potential $5,000 Monthly Income: 10 Investments To Buy And Hold For Next 10 Years

Is Bristol Myers Squibb Stock a Buy?

Enbridge

Kraft Heinz

Want Over $3,000 in Annual Dividends? Invest $20,000 in Each of These 3 Stocks

Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.

Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It

Bristol-Myers Squibb Company (NYSE:BMY ) Jefferies London Healthcare Conference November 19, 2024 4:30 AM ET Company Participants David Elkins - CFO Unidentified Company Representative On to the next fireside chat. And again, thanks, everyone, for your attendance.

Bristol-Myers Squibb Company (BMY) Jefferies London Healthcare Conference (Transcript)

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASH--BMS' Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms.

Bristol Myers Squibb's Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms

Over the weekend, Bristol Myers Squibb & Co BMY shared preliminary data from a Phase 1 study of CC-97540 (BMS-986353), a CD19-directed CAR T Cell Therapy Manufactured Using a Next-generation Process for severe, refractory autoimmune diseases.

Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases

Bristol-Myers Squibb's stock price has risen more than 25% over the past six months, reflecting significant progress in its oncology and neuroscience franchises. So, Yervoy's sales amounted to $642 million in the third quarter of 2024, increasing by 10.9% year-on-year and 1.9% quarter-on-quarter. Moreover, on September 26, 2024, the company announced the long-awaited approval of Cobenfy for the treatment of schizophrenia.

Bristol-Myers Squibb: Buy This Bargain Before It's Gone

Key Points Yields have drifted higher since the Federal Reserve cut rates in September.

6 of Wall Street's Most Beloved High-Yield Stocks Are On Sale

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CHMP--Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® plus Yervoy® for the First-Line Treatment of Adult Patients with Microsatellite.

Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CARE--Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of advanced ROS1-Positive Non-Small Cell Lung Cancer.

Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors

Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by delaying federal approval for three drugs, 1-1/2 months after a federal judge abruptly dismissed an earlier version of the case.

Bristol Myers faces renewed, $6.7 bln lawsuit over delayed cancer drug

CVS Health

They're down, but they aren't out, at least not in the eyes of patient investors.

2 Beaten-Down Dividend Stocks to Buy and Hold

News for Bristol-Myers Stock (BMY)